Related Experiment Video

Updated: Dec 9, 2025

Intradermal Inoculation of Mycobacterium avium in the Mouse Ear
09:20

Intradermal Inoculation of Mycobacterium avium in the Mouse Ear

Published on: July 3, 2025

946

Management of Drug Toxicity in Mycobacterium avium Complex Pulmonary Disease: An Expert Panel Survey

Jakko van Ingen1, Stefano Aliberti2,3, Claire Andrejak4

  • 1Center for Infectious Diseases, Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, The Netherlands.

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|September 10, 2020
PubMed

Insights

Adverse events are common in nontuberculous mycobacteria pulmonary disease treatment. Expert opinions offer guidance for managing common side effects like liver, eye, and ear toxicities.

Area of Science:

  • Pulmonology
  • Infectious Diseases
  • Pharmacology

Background:

  • Nontuberculous mycobacteria (NTM) pulmonary disease treatment frequently causes adverse events.
  • Limited evidence exists to guide the management of these treatment-related toxicities.
  • Effective management strategies are crucial for patient adherence and treatment success.

Purpose of the Study:

  • To survey expert opinions on managing common adverse events associated with NTM pulmonary disease treatment.
  • To establish consensus on the best practices for addressing specific toxicities.
  • To provide practical guidance for clinicians managing patients with NTM lung disease.

Main Methods:

  • An expert panel of pulmonologists and infectious disease specialists was convened.
  • A survey was conducted to gather opinions on the management of specific adverse events.
  • Consistent opinions were analyzed across key toxicity categories.

Main Results:

  • The expert panel reached consistent opinions on managing hepatotoxicity, ocular toxicity, ototoxicity, tinnitus, and gastrointestinal upset.
  • These consistent opinions highlight areas of expert agreement in adverse event management.
  • The survey identified specific approaches favored by experts for common side effects.

Conclusions:

  • Expert consensus provides valuable guidance for managing adverse events in NTM pulmonary disease.
  • These findings can assist clinicians in making informed decisions for individual patient care.
  • Further research may build upon these expert opinions to develop evidence-based guidelines.
Keywords:
Mycobacterium avium complexadverse eventsantibiotic treatmentazithromycinnontuberculous mycobacteria

More Related Videos

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

2.1K
Preparation of Agar Bead Embedded Mycobacterium abscessus to Inoculate Immunocompetent Mice Intratracheally05:40

Preparation of Agar Bead Embedded Mycobacterium abscessus to Inoculate Immunocompetent Mice Intratracheally

Published on: April 25, 2025

1.3K

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
375
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
330
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
623
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
636
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
2.9K
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
107